Clinical trials: Adenocarcinoma of Rectum
dMMR/MSI-H-type Rectal Adenocarcinoma
The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)
Immunotherapy may bring revolutionary changes to the preoperative neoadjuvant treatment mode for dMMR/MSI-H locally advanced rectal cancer.
- Trial name
- Neo-IT (NCT07160647)
- Testing
- Ipalolimab and Tovorilimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sir Run Run Shaw Hospital